INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the expansion of clonal hematopoietic cells that carry the Philadelphia (Ph) chromosome and are capable of terminal differentiation to every cell lineage during the chronic phase. 1 In terms of its natural history, CML typically progresses from the chronic phase to terminal blastic phase/blast crisis via an accelerated phase. 2 Blast crisis is often accompanied by additional chromosomal abnormalities in addition to the Ph chromosome as a result of secondary molecular evolution. The most common phenotype of the blasts at the time of crisis is a myeloid one, comprising approximately two-thirds of cases, which is followed by B lymphoid, megakaryocytic, erythroid, basophilic, and rarely monocytic, T lymphoid, and eosinophilic phenotypes. 3 The development of bcr-abl-targeted tyrosine kinase inhibitors (TKIs) as the treatment of chronic-phase CML has dramatically reduced the incidence of transformation of chronic-phase CML to blast crisis. 4, 5 However, it is well known that the outcome of CML patients who exhibit failure or suboptimal response to the treatment with imatinib mesylate is poor, 6 indicating that poor responders to TKI treatment have a risk of developing blast crisis of CML. In this article, we report on a patient who developed rare monocytic crisis, presumably due to poor adherence to TKI treatment.
Fluorescence in situ hybridization showed a bcr-abl fusion signal in 94.6% of marrow cells analyzed. Reverse transcriptase-polymerase chain reaction also showed the major bcr-abl transcript. A diagnosis of Ph chromosomepositive CML in chronic phase was made and the Sokal score was intermediate risk. Although imatinib mesylate was available at this time, he could not receive the treatment with this agent because of his financial circumstances. Therefore, treatment with hydroxyurea was started without complete hematological response (CHR), presumably due to his poor adherence to this treatment associated with his occupational circumstances. Although treatment with imatinib mesylate (400 mg/day) became available to him in June 2008, CHR was not obtained because of his poor adherence to the treatment. Furthermore, he discontinued the treatment for 2 months owing to his occupational circumstances in July 2009. As a result, his WBC count elevated to 350 × 10 9 /L with moderate anemia and a platelet count of 171 × 10 9 /L. A bone marrow aspirate showed sustained chronic phase of CML with the same karyotype of t(9;22). Imatinib mesylate was switched to nilotinib (800 mg/day) to obtain CHR in February 2010. The treatment with nilotinib brought about CHR ; nevertheless, he again discontinued the treatment in May 2010. After 4 months of discontinuation, his WBC count elevated to 320 × 10 9 /L, with a differential count of 1% blasts and 46% promyelocytes, and decreased platelet count of 59 × 10 9 /L. Cytogenetic analysis of bone marrow cells showed t(9;22)(q34;q11) with additional abnormalities of der (17) , add (17)(p11.2), add19(p11), and +der (22) /L with 5% blasts, 2% metamyelocytes, 4% band form, 3% segmented form, 1% eosinophils, 1% basophils, 29% monocytes, 55% lymphocytes, and 9% erythroblasts, a hemoglobin concentration of 9.1 g/dL, and a platelet count of 46 × 10 9 /L. Hemostatic examination revealed that concentrations of fibrinogen and D-dimer were 1,174 mg/dL (normally 160 to 350 mg/dL) and 2.3 μg/mL (normally below 1.0 μg/mL), respectively. Biochemical tests showed that serum concentrations of aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, lactate dehydrogenase, blood urea nitrogen, and creatinine were 14 IU/L, 12 IU/L, 0.3 mg/dL, 285 IU/L, 445 IU/L (normally 120 to 230 IU/L), 13.0 mg/dL, and 1.12 mg/dL (normally 0.5 to 1.0 mg/dL), respectively. C-reactive protein was elevated to 17.1 mg/dL (normally below 0.3 mg/dL). Serum concentration of lysozyme was as high as 180 μg/mL (normally 4.2 to 11.5 μg/mL). A bone marrow aspirate revealed hypercellularity with 90% immature monocyte-like cells (Fig. 1A) . Cytochemical analysis showed that these cells were strongly positive for a-naphthyl butyrate esterase staining (Fig. 1B) , but negative for peroxidase ( Fig. 1C ) and naphthol ASD chloroacetate esterase staining (data not shown). Flow cytometric analysis demonstrated that these immature cells were positive for CD2, CD4, CD7, CD14, CD33, CD64, and HLA-DR, but negative for CD13 and CD34. Chromosomal analysis showed t(9;22) with further additional complex abnormalities including tetrasomy 8 and trisomy 19 ( Fig. 2) (Table 1 ). These findings indicated the monocytic nature of these immature cells, and a diagnosis of monocytic crisis of CML was made. No known point mutations in bcr-abl were detected at this time point.
Since the WBC count increased from 12.7 × 10 9 /L to 130.8 × 10 9 /L 6 days after admission, he received combination chemotherapy consisting of mitoxantrone, etoposide, and cytarabine in addition to nilotinib at 400 mg/day. However, the effect of the combination chemotherapy was transient, with possible life-threatening infection ; therefore, a combination with nilotinib and hydroxyurea was started for the control of blast/immature monocyte counts. After 1 week of administration of this combination, the blast count decreased with severe neutropenia to less than 0.01 × 10 9 /L, and severe pancytope- Stenotrophomonas maltophilia in April 2011. Necropsy showed severe bone marrow hypoplasia with focal infiltration of mature leukemic cells (Fig. 3B ) and similar infiltration in the portal area of the liver (Fig. 3C ) and spleen (data not shown). In addition, necropsy specimen of the lung showed extensive alveolar hemorrhage, possibly due to Stenotrophomonas maltophilia infection (Fig. 3D) .
DISCUSSION
Monocytic crisis is a rare phenotype of blast crisis in CML. To the best of our knowledge, only 11 cases of monocytic crisis have been described in the English literature or abstracts, and all cases except for the present one were reported before the availability of imatinib mesylate. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Clinical data of these 11 and the present patients are summarized in Table 2 . Furthermore, in the era of TKI of the second generation, blast crisis itself is rare. Therefore, the facts that the present patient could not initially start treatment with imatinib mesylate and that his adherence to subsequent TKI treatments was very poor may be instructive in terms of risky situations regarding blast crisis. Indeed, the adherence to imatinib mesylate as the critical factor for achieving a cytogenetic or molecular response has been reported. 18, 19 It is speculated that bcr-abl affects the DNA repair process, and altered DNA repair leads to genomic instability, which consequently causes clonal evolution and, finally, blast crisis. 20 In the present patient, uncontrolled and sustained bcr-abl activity in CML cells may have caused the accumulation of genetic instability. Indeed, a leukemic cell line was established from bone marrow cells at the initial period of the blast crisis in the present patient. Interestingly, multiple amplification of bcr-abl was demonstrated in these cultured cells fied bcr-abl may have contributed to the genomic instability in the present patient. The loss of 17p due to -17, which was observed in the karyotype at the time of blast crisis in the present patient might have diminished the function of the p53 gene and subsequently enhanced the progression of CML. 21 In relation to possible bcr-abl-caused genetic evolution, blast crisis is often associated with additional cytogenetic and secondary molecular changes that contribute to the enhanced proliferation and survival, as well as differentiation arrest, of CML cells. 22 With the transition from CML chronic phase to blast crisis, 60% to 80% of patients acquire chromosomal changes in addition to the Ph chromosome. 23 The most common changes include double Ph chromosome, trisomy 8, trisomy 19, and isochromosome 17. 23 Previous cases of monocytic crisis also showed chromosomal abnormalities involving chromosomes 8, 19, and 22, as observed in the present case ; however, these abnormalities are not specifically restricted to monocytic crisis. Of interest, the karyotype at the time of blast crisis was quite different from that during the accelerated phase in the present patient (Fig. 2) ; the karyotype during the crisis was hyperdiploid with 53 to 58 chromosomes and contained many trisomies and some monosomies. As a speculation for the mechanism of hyperdiploid change, previous treatment with hydroxyurea may have contributed to the development of chromosomal abnormalities because a review regarding cytogenetic evolution in CML 20 indicated a close relationship between previous treatment with hydroxyurea or busulfan and hyperdiploid changes with+8, +Ph, i(17q), +19, +21, +17, -7, or -17 during the advanced stage of CML, many of which were present in the karyotype during the crisis in the present patient. Therefore, previous hydroxyurea treatment and bcr-abl amplification might have caused multi-step molecular genetic evolution resulting in the hyperdiploid tumor cells from the period of accelerated phase to that of blast crisis in the present patient.
Resistance of CML cells to TKIs is induced by several mechanisms and is frequently associated with a specific point mutation in the bcr-abl kinase domain. 24 There have been several reports regarding other mechanisms of resistance, including the amplification of bcr-abl, over-expression of the multidrug resistance P-glycoprotein, and activation of alternative signaling pathways, such as those involving the Src family kinases, Ras, phosphatidylinositol 3-kinase, Janus kinase, and the signal transducer and activator of transcription. 25 CML cells in the present patient apparently showed resistance to imatinib and dasatinib, although the exact efficacy and resistance were unclear because of poor adherence to each treatment. Nevertheless, no known and available bcr-abl point mutation was detected at any phase of CML. The amplification of bcr-abl as observed in the established cell line, therefore, may have contributed to the resistance to imatinib in the present patient.
After the onset of blast crisis, we treated the present patient with nilotinib, which had brought about CHR in the chronic phase of CML. The efficacy of nilotinib for CML in the accelerated phase or blast crisis may have been established. 26, 27 This agent suppressed the proliferation of leukemic cells in the peripheral blood for a long time in the present patient, although normal hematopoiesis hardly recovered, and focally residual leukemic cells were present in the bone marrow, liver, and spleen. Extensive bone marrow necrosis observed during the period of severe leucopenia under the treatment with nilotinib may have contributed to the recovery failure of normal hematopoiesis. Bone marrow necrosis in CML has been reported in at least 14 patients, most of whom were in the blastic phase. 28 The necrosis results from cellular hypoxia due to ischemia of marrow microcirculation as a consequence of inflammatory damage or mechanical obstruction. 29 Bone marrow necrosis has also been associated with the use of imatinib mesylate. [29] [30] [31] These reports suggest that overgrowth of leukemic cells during blast crisis of CML causes failure of the microcirculation. Thus, the causative role of nilotinib in bone marrow necrosis should be investigated in patients with CML blast crisis in future.
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